These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17645051)

  • 1. [Heart rate as a cardiovascular risk factor: potential clinical benefit with ivabradine].
    Purcell H; Mach F
    Rev Med Suisse; 2007 May; 3(113):1375-8, 1381-2. PubMed ID: 17645051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.
    DiFrancesco D; Camm JA
    Drugs; 2004; 64(16):1757-65. PubMed ID: 15301560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ivabradine: I(f) inhibition in the management of stable angina pectoris and other cardiovascular diseases.
    Tardif JC
    Drugs Today (Barc); 2008 Mar; 44(3):171-81. PubMed ID: 18536779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor.
    Borer JS; Le Heuzey JY
    Am J Ther; 2008; 15(5):461-73. PubMed ID: 18806523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ivabradine in stable coronary artery disease without clinical heart failure.
    Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R;
    N Engl J Med; 2014 Sep; 371(12):1091-9. PubMed ID: 25176136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart rate as a treatable cardiovascular risk factor.
    Tardif JC
    Br Med Bull; 2009; 90():71-84. PubMed ID: 19474056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ivabradine: beyond heart rate control.
    Riccioni G; Vitulano N; D'Orazio N
    Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the management of heart failure: the role of ivabradine.
    Müller-Werdan U; Stöckl G; Werdan K
    Vasc Health Risk Manag; 2016; 12():453-470. PubMed ID: 27895488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina.
    Sulfi S; Timmis AD
    Int J Clin Pract; 2006 Feb; 60(2):222-8. PubMed ID: 16451297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study.
    Majewski S; Slomka S; Zielinska-Wyderkiewicz E; Ciebiada M; Gorski P
    Am J Cardiovasc Drugs; 2012 Jun; 12(3):179-88. PubMed ID: 22409211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resting heart rate: risk indicator and emerging risk factor in cardiovascular disease.
    Böhm M; Reil JC; Deedwania P; Kim JB; Borer JS
    Am J Med; 2015 Mar; 128(3):219-28. PubMed ID: 25447617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The discovery of the selective I(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease.
    Vilaine JP
    Pharmacol Res; 2006 May; 53(5):424-34. PubMed ID: 16638639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
    Bruguera Cortada J; Varela A
    Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ivabradine (Procoralan)].
    Lancellotti P
    Rev Med Liege; 2008 Apr; 63(4):220-4. PubMed ID: 18575078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Heart rate reduction as a therapeutic strategy: novel options].
    Hoppe UC
    Internist (Berl); 2006 Dec; 47(12):1289-93. PubMed ID: 17077980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease.
    Dillinger JG; Maher V; Vitale C; Henry P; Logeart D; Manzo Silberman S; Allée G; Levy BI
    Hypertension; 2015 Dec; 66(6):1138-44. PubMed ID: 26418022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ivabradine--the first selective and specific I(f) inhibitor, novel preparation for treatment of stable angina].
    Belousov IuB; Erofeeva SB; Maneshina OA
    Kardiologiia; 2006; 46(8):36-48. PubMed ID: 17047598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Heart rate modulation in stable ischemic heart disease: what we have learned from the SIGNIFY study?].
    Perna GP; Battistoni I; Angelini L
    G Ital Cardiol (Rome); 2015 Mar; 16(3):155-60. PubMed ID: 25837459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
    Fox K; Ford I; Steg PG; Tendera M; Ferrari R;
    Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.
    Ferrari R; Ceconi C
    Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):959-73. PubMed ID: 21878041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.